NumerixS Investment Technologies’s Travere Therapeutics TVTX Stock Holding History

NumerixS Investment Technologies’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,400	Closed	-$78K	–	1349
2019 Q1	$78K	Buy	+3,400	New	+$75.1K	0.01%	923
2018 Q3	–	Sell	-1,000	Closed	-$26K	–	1374
2018 Q2	$26K	Buy	+1,000	New	+$26.6K	0.01%	996
2018 Q1	–	Sell	-800	Closed	-$17K	–	1288
2017 Q4	$17K	Sell	800 -1,800	-69%	-$41.1K	﹤0.01%	1019
2017 Q3	$65K	Buy	+2,600	New	+$57.2K	0.01%	870
2017 Q2	–	Sell	-5,100	Closed	-$94K	–	1354
2017 Q1	$94K	Buy	+5,100	New	+$99.8K	0.01%	897

Other funds holding TVTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NumerixS Investment Technologies's TVTX Position: Q2 2019 in Review

NumerixS Investment Technologies sold out of Travere Therapeutics (TVTX) in Q2 2019, closing a stake of 3,400 shares — an estimated $78K sold.

NumerixS Investment Technologies first reported a position in TVTX in Q1 2017 and held it in 5 quarters. The position peaked at $94K in Q1 2017. 122 funds tracked by Wall St. Rank hold TVTX as of Q2 2019.

NumerixS Investment Technologies reported no remaining Travere Therapeutics position as of Q2 2019 after selling out during the quarter.
NumerixS Investment Technologies sold 3,400 Travere Therapeutics shares in Q2 2019, an estimated $78K.
NumerixS Investment Technologies first reported a position in Travere Therapeutics in Q1 2017 and held it in 5 quarters.
NumerixS Investment Technologies's Travere Therapeutics position peaked at $94K in Q1 2017.
122 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2019.

Based on NumerixS Investment Technologies's 13F filing for Q2 2019, filed 13 Aug 2019.